{"id":"NCT00420992","sponsor":"Pfizer","briefTitle":"A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2007-01-11","resultsPosted":"2009-10-30","lastUpdate":"2013-09-20"},"enrollment":547,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis","Chronic Pain"],"interventions":[{"type":"DRUG","name":"ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)","otherNames":["Embeda"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ALO-01","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.","primaryOutcome":{"measure":"Mean Change From Randomization to 12 Weeks Following Randomization in Diary Brief Pain Inventory Score of Average Pain (Daily Scores of Average Pain Averaged Over 7 Days)","timeFrame":"randomization to 12 weeks following randomization","effectByArm":[{"arm":"ALO-01","deltaMin":-0.2,"sd":1.94},{"arm":"Placebo","deltaMin":0.3,"sd":2.05}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0445"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":81,"countries":["United States"]},"refs":{"pmids":["26695349"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":171},"commonTop":["Constipation","Nausea","Somnolence","Vomiting","Diarrhoea"]}}